Division of Neurology, Faculty of Medicine, The University of British Columbia and Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada.
Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada.
Mult Scler. 2019 Jul;25(8):1092-1101. doi: 10.1177/1352458518783662. Epub 2018 Jul 6.
The multiple sclerosis (MS) prodrome is poorly characterized.
To phenotype the MS prodrome via health care encounters.
Using data from a population-based cohort study linking administrative and clinical data in four Canadian provinces, we compared physician and hospital encounters and prescriptions filled (via International Classification of Diseases chapters, physician specialty or drug classes) for MS subjects in the 5 years before the first demyelinating claim in an administrative cohort or the clinical symptom onset in an MS clinic-derived cohort, to age-, sex- and geographically matched controls. Rate ratios (RRs), 95% confidence intervals (95% CIs) and proportions were estimated.
The administrative and clinical cohorts included 13,951/66,940 and 3202/16,006 people with and without MS (cases/controls). Compared to controls, in the 5 years before the first demyelinating claim or symptom onset, cases had more physician and hospital encounters for the nervous (RR (range) = 2.31; 95% CI: 1.05-5.10 to 4.75; 95% CI: 3.11-7.25), sensory (RR (range) = 1.40; 95% CI: 1.34-1.46 to 2.28; 95% CI: 1.72-3.02), musculoskeletal (RR (range) = 1.19; 95% CI: 1.07-1.33 to 1.70; 95% CI: 1.57-1.85) and genito-urinary systems (RR (range) = 1.17; 95% CI: 1.05-1.30 to 1.59; 95% CI: 1.48-1.70). Cases had more psychiatrist and urologist encounters (RR (range) = 1.48; 95% CI: 1.36-1.62 to 1.80; 95% CI: 1.61-2.01), and higher proportions of musculoskeletal, genito-urinary or hormonal-related prescriptions (1.1-1.5 times higher, all < 0.02). However, cases had fewer pregnancy-related encounters than controls (RR = 0.78; 95% CI: 0.71-0.86 to 0.88; 95% CI: 0.84-0.92).
Phenotyping the prodrome 5 years before clinical recognition of MS is feasible.
多发性硬化症(MS)前驱期的特征描述较差。
通过医疗保健接触来表现 MS 前驱期的表型。
使用来自一个基于人群的队列研究的数据,该研究将四个加拿大省份的行政和临床数据联系起来,我们比较了在行政队列中首次脱髓鞘索赔前 5 年或在 MS 诊所衍生队列中临床症状出现前,MS 受试者的医生和医院就诊次数以及处方填写情况(通过国际疾病分类章节、医生专业或药物类别)与年龄、性别和地理位置匹配的对照组。估计率比(RR)、95%置信区间(95%CI)和比例。
行政和临床队列分别包括 13951/66940 和 3202/16006 名有和没有 MS(病例/对照)的人。与对照组相比,在首次脱髓鞘索赔或症状出现前的 5 年内,病例的医生和医院就诊次数更多,涉及神经系统(RR(范围)=2.31;95%CI:1.05-5.10 至 4.75;95%CI:3.11-7.25)、感觉(RR(范围)=1.40;95%CI:1.34-1.46 至 2.28;95%CI:1.72-3.02)、肌肉骨骼(RR(范围)=1.19;95%CI:1.07-1.33 至 1.70;95%CI:1.57-1.85)和生殖泌尿系统(RR(范围)=1.17;95%CI:1.05-1.30 至 1.59;95%CI:1.48-1.70)。病例的精神科和泌尿科就诊次数更多(RR(范围)=1.48;95%CI:1.36-1.62 至 1.80;95%CI:1.61-2.01),肌肉骨骼、生殖泌尿系统或激素相关处方的比例更高(1.1-1.5 倍,均<0.02)。然而,病例的妊娠相关就诊次数少于对照组(RR=0.78;95%CI:0.71-0.86 至 0.88;95%CI:0.84-0.92)。
在临床识别 MS 前 5 年对前驱期进行表型分析是可行的。